For more than fifty years, estrogen has quietly held a place in the oncologist's cabinet as an unlikely weapon against advanced breast cancer — effective in roughly a third of patients, yet chronically underused because its mechanism remained a mystery. Researchers at Dartmouth Cancer Center have now illuminated that mystery, revealing that estrogen inflicts DNA damage on cancer cells, and that pairing it with a PARP inhibitor — a drug that blocks cellular repair — transforms that damage into something the cancer cannot survive. The discovery matters not only for what it explains, but for what
News-Medical.net
· Jul 14, 2023
· health
· 1 min de leitura
High
Apuração: Verificado
Estrogen-PARP inhibitor combo shows promise for advanced ER+ breast cancer
◉
Health & Medicine
8098 artigos relacionados
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 100% correspondência
Blood test could predict Covid-19 mortality risk, study finds
BreakingNews.ie · 99% correspondência
Hadassah performs world's first alpha radiation treatment for recurren…
jpost.com · 99% correspondência
Dr. Reddy's Wins Semaglutide Approval as Novo Nordisk Patent Challenge…
NDTV Profit · 99% correspondência
EU safety committee reviews reports of menstrual changes after mRNA CO…
CNBC · 99% correspondência
Cobertura Relacionada
The Guardian · Aug 20
Hundreds of thousands await GCSE results as gender gap narrows to 10-year low
Hundreds of thousands of UK students received GCSE results showing overall grade improvements in 2025, with the gender g…
The Straits Times · Aug 20 Ebola spreads beyond Congo epicentre, overwhelming treatment capacityEbola cases in DRC are accelerating outside the initial Ituri epicenter, with North Kivu and Haut-Uélé provinces experie…
Science Daily · Aug 20 1,000+ genetic switches explain why women face higher autoimmune disease riskResearchers identified over 1,000 genetic switches that function differently in male and female immune cells, explaining…
News-Medical · Aug 20 Brain's Local Wiring May Buffer Cognitive Decline in Older AdultsUSC researchers found that white matter integrity helps protect cognitive function in older adults by compensating for g…
Viés e Enquadramento
⚖
Article presents promising preclinical research on estrogen-PARP inhibitor combination with optimistic framing, limited critical perspective on trial stage or limitations.
Bias Direction
center
Confidence
MED
Optimistic scientific progress narrative emphasizing potential benefits and researcher enthusiasm, with minimal discussion of uncertainties or limitations typical of early-stage research.
shows promise
greatly expand
new option
effective
under-utilized
Potential side effects or safety concerns of the combination therapy
Expert skepticism or cautionary views from independent researchers
Discussion of why this approach hasn't been pursued earlier if estrogen therapy has 50+ years of use
Realistic timeline and probability of clinical translation
Comparison to existing standard-of-care treatments for advanced ER+ breast cancer
Patient accessibility or cost considerations
Impacto Geopolítico
🌎
Medical research breakthrough in cancer treatment; no direct geopolitical implications identified.
Escalation Risk
low
Confidence
HIGH
Lente Econômica
📈
Dartmouth researchers demonstrate estrogen-PARP inhibitor combination effectively treats advanced ER+ breast cancer, potentially expanding PARP inhibitor market and improving treatment options for 30% of resistant cases.
Market Signal
bullish
Confidence
MED
Pharmaceutical/Oncology
Biotechnology
Healthcare/Medical Services
Medical Devices
Health Insurance
Patients with advanced ER+ breast cancer gain potential new treatment option with improved efficacy. Expanded PARP inhibitor use could increase out-of-pocket costs for some patients, though may reduce overall treatment costs if it prevents progression to more expensive interventions.
FDA may expedite review of estrogen-PARP inhibitor combinations for oncology indications. Insurance companies may need to update coverage policies for PARP inhibitors in broader patient populations. Potential for expanded clinical trial funding and research investment in combination therapies.